JP2007525491A - Ｇｐｒ４９の使用による、神経変性疾患の治療 - Google Patents

Ｇｐｒ４９の使用による、神経変性疾患の治療 Download PDF

Info

Publication number
JP2007525491A
JP2007525491A JP2006549895A JP2006549895A JP2007525491A JP 2007525491 A JP2007525491 A JP 2007525491A JP 2006549895 A JP2006549895 A JP 2006549895A JP 2006549895 A JP2006549895 A JP 2006549895A JP 2007525491 A JP2007525491 A JP 2007525491A
Authority
JP
Japan
Prior art keywords
gpr49
secretase
protein
beta
gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006549895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007525491A5 (enExample
Inventor
ホプフ，カルステン
ドリューズ，ジェラルド
ラフナー，ハインツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellzome GmbH
Original Assignee
Cellzome GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome GmbH filed Critical Cellzome GmbH
Publication of JP2007525491A publication Critical patent/JP2007525491A/ja
Publication of JP2007525491A5 publication Critical patent/JP2007525491A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2006549895A 2004-01-29 2004-11-29 Ｇｐｒ４９の使用による、神経変性疾患の治療 Withdrawn JP2007525491A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP04001894 2004-01-29
EP04001895 2004-01-29
EP04007447 2004-03-26
EP2004004889 2004-05-07
EP2004004891 2004-05-07
PCT/EP2004/013539 WO2005074980A1 (en) 2004-01-29 2004-11-29 Treatment of neurodegenerative diseases by the use of gpr49

Publications (2)

Publication Number Publication Date
JP2007525491A true JP2007525491A (ja) 2007-09-06
JP2007525491A5 JP2007525491A5 (enExample) 2007-12-13

Family

ID=38556372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006549895A Withdrawn JP2007525491A (ja) 2004-01-29 2004-11-29 Ｇｐｒ４９の使用による、神経変性疾患の治療

Country Status (11)

Country Link
US (1) US20080025969A1 (enExample)
EP (1) EP1713501B1 (enExample)
JP (1) JP2007525491A (enExample)
AT (1) ATE383870T1 (enExample)
AU (1) AU2004315111B2 (enExample)
CA (1) CA2554353A1 (enExample)
DE (1) DE602004011400T2 (enExample)
DK (1) DK1713501T3 (enExample)
ES (1) ES2300852T3 (enExample)
PT (1) PT1713501E (enExample)
WO (2) WO2005074980A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
EP2002714A1 (en) * 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2022848A1 (en) * 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
WO2010016766A2 (en) * 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8604074B2 (en) 2009-01-09 2013-12-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
WO2012006419A2 (en) * 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
EP2887803A4 (en) 2012-08-24 2016-08-03 Univ Texas PRO-NEUROGENIC COMPOUNDS
CN104903308B (zh) 2013-01-10 2018-06-08 默克专利股份有限公司 作为抗疟药的哌啶基咔唑类
US9902713B2 (en) 2013-11-11 2018-02-27 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
CN106573918B (zh) 2014-07-04 2020-06-16 默克专利股份有限公司 具有抗寄生虫活性的氮杂环庚烷基衍生物和包含它们的药物组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) * 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
AU4589297A (en) * 1996-10-07 1998-05-05 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
AU775525B2 (en) * 1999-01-22 2004-08-05 Auckland Technology Enabling Corporation Limited Vaccine-mediated treatment of neurological disorders
DE19941039A1 (de) * 1999-08-28 2001-03-01 Boehringer Ingelheim Pharma gamma-Sekretase in vitro Testsystem
GB0005894D0 (en) * 2000-03-10 2000-05-03 Glaxo Group Ltd Assay
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
EP1354950A4 (en) * 2000-12-28 2005-01-12 Asahi Kasei Pharma Corp ACTIVATION GENE OF NF-KB
WO2002060867A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
US20050288212A1 (en) * 2002-06-26 2005-12-29 Cellzome Ag Components of the presenilin-complex
EP1380644A1 (en) * 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
US7056685B1 (en) * 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
US7189539B2 (en) * 2003-11-25 2007-03-13 Bristol-Myers Squibb Company Polynucleotide encoding a human relaxin receptor, HGPRBMY5v1

Also Published As

Publication number Publication date
WO2005074980A1 (en) 2005-08-18
DK1713501T3 (da) 2008-05-26
DE602004011400D1 (de) 2008-03-06
ES2300852T3 (es) 2008-06-16
DE602004011400T2 (de) 2009-01-22
EP1713501B1 (en) 2008-01-16
ATE383870T1 (de) 2008-02-15
AU2004315111B2 (en) 2010-03-04
AU2004315111A1 (en) 2005-08-18
WO2005074971A1 (en) 2005-08-18
EP1713501A1 (en) 2006-10-25
CA2554353A1 (en) 2005-08-18
PT1713501E (pt) 2008-04-30
US20080025969A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
EP1815255B1 (en) Use of eph receptor inhibitors for the treatment of neurodegenerative diseases
CN103282374B (zh) 用于治疗神经变性病症和阿尔茨海默病并改善正常记忆的方法和组合物
EP1670903B1 (en) Treatment of neurodegenerative diseases
EP1713501B1 (en) Treatment of neurodegenerative diseases by the use of gpr49
EP1786442B1 (en) Treatment of neurodegenerative diseases by the use of degs inhibitors
JP2007523893A (ja) Ａｔｐ７ａの使用による、神経変性疾患の治療
EP1732649B1 (en) Treatment of neurodegenerative diseases by the use of laptm4b
US20080038249A1 (en) Treatment Of Neurodegenerative Diseases By The Use Of Laptm4a
JP4772684B2 (ja) スクリーニング方法
HK1100746A (en) Treatment of neurodegenerative diseases by the use of gpr49

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071024

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100506